Table 1.
Baseline Patients’ Characteristics.
| Patient characteristics | PPI group 71 patients |
VPZ group 59 patients |
p | |||||
|---|---|---|---|---|---|---|---|---|
| Age, year, median±SD | 77±6 | 76±7 | 0.8 | |||||
| Sex, male, n (%) | 56 (79) | 52 (88) | 0.06 | |||||
| Comorbidity, n (%) | Hypertension | 57 (80) | 45 (76) | 0.57 | ||||
| Diabetes mellitus | 9 (13) | 19 (32) | 0.007 | |||||
| Renal failure on hemodialysis | 0 (0) | 1 (1.6) | 0.2 | |||||
| Reasons for antithrombotic therapy, n (%) | Ischemic heart disease | 21 (30) | 17 (31) | 0.92 | ||||
| Arrhythmia | 10 (14) | 12 (20) | 0.34 | |||||
| Cerebrovascular disease | 17 (24) | 22 (37) | 0.1 | |||||
| Others | 8 (11) | 2 (3) | 0.09 | |||||
| Type of antithrombotic agents, n (%) | Antiplatelet monotherapy | 46 (65) | 29 (49) | 0.07 | ||||
| Antiplatelet dual therapy | 10 (14) | 15 (25) | 0.1 | |||||
| Anticoagulant monotherapy | 11 (15) | 11 (19) | 0.6 | |||||
| Combination of antiplatelet and anticoagulant | 4 (6) | 4 (7) | 0.7 | |||||
| Number of tumors, n (%) | 1 | 53 (75) | 41 (69) | 0.5 | ||||
| 2-6 | 18 (25) | 18 (31) |
SD: standard deviation, n: number, PPI: proton-pump inhibitor, VPZ: vonoprazan